NuvaRing and Laboratory Values: Hematocrit and Cortisol
NuvaRing does not cause clinically significant elevations in hematocrit, but it does cause substantial increases in total cortisol levels through elevation of cortisol-binding globulin (CBG), though free cortisol typically remains unchanged. 1
Cortisol Elevation
Mechanism and Magnitude
The ethinyl estradiol component in NuvaRing increases cortisol-binding globulin (CBG), which in turn elevates total serum cortisol levels. 1 However, this effect is notably less pronounced with NuvaRing compared to combined oral contraceptives (COCs) due to lower systemic estrogen exposure. 1, 2
- In a comparative study, total cortisol and CBG levels rose significantly less during NuvaRing use than during COC use (p=0.0002 at cycle 3; p<0.0001 at cycle 6). 1
- The lower systemic exposure to ethinyl estradiol with NuvaRing (approximately half that of a 30 mcg EE-containing COC) results in more modest increases in binding proteins. 2
- Free cortisol index (FCI) typically remains unchanged, indicating that the increase in total cortisol parallels the increase in CBG, maintaining normal biologically active cortisol levels. 3
Clinical Implications
These changes are not considered clinically relevant for adrenal function in most women. 1 However, there are important caveats:
- In rare cases, some individuals may demonstrate exaggerated increases in total cortisol levels that can appear alarming on laboratory testing, with levels potentially reaching 50-60 mcg/dL (normal range 8-25 mcg/dL). 4
- Laboratory interpretation requires awareness: elevated total cortisol in NuvaRing users does not indicate Cushing's syndrome if the 24-hour urine free cortisol is normal and the patient lacks clinical signs of hypercortisolism. 4
- If extreme hypercortisolemia is detected, discontinuing NuvaRing for 2 months typically normalizes both total cortisol and CBG levels. 4
Other Adrenal Effects
- Dehydroepiandrosterone sulfate (DHEA-S) levels do not change with NuvaRing use. 1
- The overall impact on adrenal function is minimal and without clinical consequences in healthy women. 1
Hematocrit
There is no evidence that NuvaRing causes elevation in hematocrit. The available guidelines and drug labeling do not identify hematocrit changes as an adverse effect of NuvaRing. 5, 6
- The FDA label for NuvaRing does not list hematocrit elevation among its effects on laboratory tests. 6
- Combined hormonal contraceptives may affect various coagulation factors (increased prothrombin and factors VII, VIII, IX, and X), but hematocrit is not among the affected parameters. 6
- If hematocrit elevation is observed in a NuvaRing user, alternative causes should be investigated rather than attributing it to the contraceptive ring.
Laboratory Monitoring Considerations
Routine monitoring of cortisol or hematocrit is not indicated for NuvaRing users unless clinically indicated by symptoms or other medical conditions. 5
When interpreting laboratory results in NuvaRing users, clinicians should be aware that:
- Thyroid-binding globulin (TBG) increases, leading to elevated total thyroid hormone levels while free T4 remains normal. 6
- Sex hormone-binding globulin (SHBG) increases markedly with NuvaRing, actually more so than with some COCs. 7
- Triglycerides may increase, though the lipid profile impact is generally minimal. 6, 7